Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emapticap pegol - NOXXON Pharma AG

Drug Profile

Emapticap pegol - NOXXON Pharma AG

Alternative Names: NOX-E36

Latest Information Update: 12 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NOXXON Pharma AG
  • Class Antineoplastics; Nucleotide aptamers; Polyethylene glycols
  • Mechanism of Action Chemokine CCL2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic nephropathies
  • Phase I Solid tumours
  • Preclinical Liver cancer; Pancreatic cancer

Most Recent Events

  • 24 Oct 2019 Preclinical trials in Liver cancer in Germany (unspecified route)
  • 24 Oct 2019 Preclinical trials in Pancreatic cancer in Germany (unspecified route)
  • 08 May 2019 NOXXON Pharma plans a clinical trial for Non-small cell lung cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top